Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a transcription factor that can influence various cellular processes, including inflammation, apoptosis, and cell proliferation. As people age, the regulation of NF-κB becomes increasingly dysregulated, leading to chronic inflammation, a hallmark of many age-related diseases. Persistent activation of NF-κB has been implicated in several diseases, including cardiovascular diseases, neurodegenerative disorders, and cancer.
Fig. 1 Schematic illustration depicting NF-κB as a central factor in pro-aging and longevity pathways. (Tilstra JS, et al., 2011)
CD BioSciences specializes in offering innovative anti-aging drug discovery approaches to combat aging and aging-related diseases. By understanding and manipulating the NF-κB pathway, we help clients develop targeted therapeutics that have the potential to slow the aging process.
Types of Anti-Aging Drugs Targeting NF-κB We Can Develop
We help clients develop natural and synthetic anti-aging drugs that have the potential to inhibit NF-κB activation. We also help explore how these drugs targeting NF-κB pathways reduce the inflammatory response and prevent the SASP, thereby mitigating the effects of aging. We are also developing drugs that suppress NF-κB activation by delivering specific genes, which may be particularly effective in combating age-related diseases.
How Do We Develop Anti-Aging Drugs Targeting NF-κB?
CD BioSciences offers a comprehensive suite of services for the discovery of anti-aging drugs targeting the NF-κB signaling pathway.
Drug screening and optimization
Our high-throughput screening platform allows the rapid identification of potential drug candidates that can modulate NF-κB activation. We offer a variety of assays, including reporter gene assays, ELISA-based assays, and cell-based imaging assays, to detect changes in NF-κB activation. Hits identified in the primary screen are then subjected to secondary screens to confirm their activation. We further help clients structurally modify the hits to improve their potency, selectivity, and pharmacokinetic properties. Our experts perform this process to ensure the efficient development of lead candidates.
In vitro and in vivo validation
CD BioSciences employs a comprehensive approach to validate the activation of anti-aging drugs targeting NF-κB pathways both in vitro and in vivo. We provide a selection of cell lines to support in vitro services focused on aging and age-related disease research. Our services are designed to unveil the mechanism of action of our drug candidates and assess their efficacy in reducing NF-κB activation and the associated inflammatory response. We further help clients evaluate the impact of drugs on cellular senescence and SASP using senescence markers and secretome analysis. We also offer in vivo services using animal models that recapitulate the human aging process. Our models allow clients to assess the pharmacokinetics, pharmacodynamics, and safety of drugs.
Targeting NF-κB in Aging-Related Diseases
- Aging-related neurodegenerative diseases. NF-κB-mediated neuroinflammation is a significant contributor to age-related neurological disorders such as Alzheimer's disease and Parkinson's disease. We help clients develop anti-aging drugs that inhibit NF-κB pathways to reduce neuroinflammation, protect neuronal cells, and improve cognitive function.
- Age-related cardiovascular diseases. By targeting the NF-κB signaling pathway, we help clients develop anti-aging drugs that have the potential to mitigate inflammation in vascular tissues, improve endothelial function, and reduce the risk of atherosclerosis.
- Age-related eye diseases. Our experts at CD BioSciences assist clients in exploring the use of NF-κB inhibitors to combat age-related macular degeneration and glaucoma and preserve vision.
The exploration of NF-κB as a target for anti-aging drug discovery holds immense potential for extending healthspan and combating age-related diseases. CD BioSciences offers advanced drug discovery services to develop innovative therapies targeting NF-κB signaling pathways. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- García-García VA, et al. Role of NF-κB in Ageing and Age-Related Diseases: Lessons from Genetically Modified Mouse Models. Cells, 2021, 10 (8): 1906.
- Tilstra JS, et al. NF-κB in Aging and Disease. Aging Dis, 2011, 2 (6): 449-65.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
